Are insulin analogs FDA-approved, and what does the research show?

See the FDA status of every peptide, updated weekly.

What are insulin analogs?

Insulin analogs are man-made versions of insulin, the hormone that lowers blood sugar ¹, ², ³. An analog is human insulin with a small change: each label says its drug "differs from human insulin" at named amino acids, the building blocks of proteins ¹, ², ³. FDA counts "insulin and insulin analogs" among protein products ⁶. Each label says its insulin is produced with recombinant DNA, a method in which a microbe carries the gene for the protein ¹, ², ³. The microbe is yeast on Levemir's label and a laboratory strain of the bacterium E. coli on the other two ¹, ², ³.

They are diabetes medicines, not wellness, weight-loss or performance peptides, and none of the three labels names such a use ¹, ², ³. Each label's patient leaflet says its insulin is used "to control high blood sugar in adults and children with diabetes mellitus" ¹, ², ³. Diabetes mellitus is the condition of lasting high blood sugar, and type 1 and type 2 are its two main forms. The labels' trials enrolled people with each form ¹, ², ³. Each label's patient leaflet calls its drug a "man-made insulin" ¹, ², ³.

The labels sort the three by speed. Insulin lispro, sold as Humalog, is "a rapid-acting human insulin analog" ². Insulin glargine (Lantus) and insulin detemir (Levemir) are each "a long-acting human insulin analog" ¹, ³. Each label gives injection under the skin as the route, and Humalog's also allows intravenous use under medical supervision ¹, ², ³.

Are insulin analogs FDA-approved?

FDA has approved all three insulin analogs covered here ¹, ², ⁴; lispro (Humalog) and glargine (Lantus) are marketed by prescription ², ⁴, ³, and detemir's product, Levemir, is listed as discontinued ⁴. FDA's Purple Book, its database of licensed biological products, records each status: its October 2026 data marks a prescription product "Rx" and a discontinued one "Disc" ⁴. The Purple Book's glossary defines "Disc." as "Discontinued Status- The product has been discontinued" ⁷. Drugs@FDA still lists two Levemir products, Levemir and Levemir FlexTouch, as "Prescription" ⁵.

The database calls them licensed rather than approved, for a legal reason. Insulins and insulin analogs were historically approved as drugs, under new drug applications ⁶. On March 23, 2020, by law, each such approval for a biological product was "deemed to be a license for the biological product" ⁶. FDA's term for that license is an approved biologics license application, or BLA ⁶.

Insulin lispro: the Purple Book's October 2026 data lists Eli Lilly's Humalog under BLA 020563, with approval dates from June 14, 1996, and the licensure "Licensed" ⁴. A second application, BLA 205747, has two presentations, both marketed by prescription ⁴. Humalog's label gives the approved use as "to improve glycemic control in adult and pediatric patients with diabetes mellitus" ². Glycemic control means keeping blood sugar within a target range.

Insulin glargine: Sanofi's Lantus sits under BLA 021081, with approval dates from April 20, 2000, and the licensure "Licensed" ⁴. Its label carries the same indication in the same words, with one limit: Lantus "is not recommended for the treatment of diabetic ketoacidosis" ³. Levemir's patient leaflet explains that term as "increased ketones in the blood or urine" ¹.

Insulin detemir: Novo Nordisk's Levemir sits under BLA 021536, with approval dates from June 16, 2005 ⁴. All five Levemir presentations are listed as discontinued, and the file lists no other insulin detemir product, so it shows none as marketed ⁴. Discontinued is a marketing status, not a withdrawal of approval, and the same record still gives Levemir's licensure as "Licensed" ⁴. The sources cited here give no date and no reason for the discontinuation ¹, ⁴. Levemir's label, revised December 2022, carried the same indication as the other two and the same ketoacidosis limit as Lantus ¹.

Humalog and Lantus are prescription medicines: the Purple Book lists them "Rx," and their cartons read "Rx only" ², ⁴, ³. The same file lists other insulin lispro and insulin glargine products under other brand names, and they are not described here ⁴.

How do insulin analogs work?

They work as insulin does, by each FDA label's own account. Lantus's label says, "The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism" ³. Glucose is blood sugar. The Lantus and Levemir labels say insulin and its analogs lower it "by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production" ¹, ³. In plain words, muscle and fat take sugar out of the blood and the liver releases less, and Humalog's label says nearly the same ².

Insulin does more than move sugar. The Lantus label says it "inhibits lipolysis and proteolysis, and enhances protein synthesis" ³. Lipolysis is the breakdown of fat and proteolysis the breakdown of protein.

On these three labels, the amino acid changes alter the insulin's timing, not its action ¹, ², ³. In insulin lispro, two neighboring amino acids on the B chain, one of insulin's two chains, are swapped ². Its label reports "a more rapid onset of action and a shorter duration of activity than regular human insulin" ². It also says one unit "has the same glucose-lowering effect as one unit of regular human insulin" ².

Insulin glargine has one amino acid replaced and two added ³. Its label describes "a slower, more prolonged absorption and a relatively constant concentration/time profile over 24 hours with no pronounced peak in comparison to NPH insulin" ³. NPH is a human insulin preparation, a comparator in the Lantus and Levemir trials ¹, ³. Insulin detemir has one amino acid removed and a fatty acid chain attached ¹. Its label says the molecules cling to one another at the injection site and bind to albumin, a blood protein, and that both slow it ¹.

What does the research show?

All three stand at the level "Approved for a use," because FDA approved each on randomized trials in people with diabetes ¹, ², ³. Randomized means the treatment was assigned by chance. The trials were also open-label, meaning patients and doctors knew which insulin was given, and most compared one insulin with another ¹, ², ³. HbA1c, or glycated hemoglobin, is a blood test of sugar control over the preceding months.

Approved by FDA to improve glycemic control, insulin lispro was studied in a 12-month randomized trial in type 1 diabetes ². It enrolled patients aged 12 to 70, 81 on Humalog and 86 on regular human insulin ². HbA1c changed by minus 0.1 percentage points on Humalog and plus 0.1 on regular insulin ². The label calls glycemic control "similar in the two treatment groups" ².

In type 2 diabetes, 722 insulin-treated adults took Humalog for three months and regular insulin for three, in random order ². HbA1c fell 0.7 percentage points on each ². An 8-month study of the same crossover kind, in 463 patients aged 9 to 19 with type 1 diabetes, found glycemic control "comparable" between the two ².

Insulin glargine's label rests on open-label, randomized trials against NPH insulin ³. They enrolled 2,327 adults and 349 children with type 1 diabetes and 1,563 adults with type 2 ³. The label sums them up: "In general, the reduction in glycated hemoglobin (HbA1c) with LANTUS was similar to that with NPH insulin" ³.

In one of them, 570 adults with type 2 diabetes added Lantus or NPH to their diabetes pills for 52 weeks ³. HbA1c fell 0.5 percentage points in the 289 on Lantus and 0.4 in the 281 on NPH ³. The difference was minus 0.1 points, with a 95 percent confidence interval of minus 0.3 to plus 0.1 ³. A confidence interval is the span of values the true difference plausibly falls in, and this one includes zero.

A published trial of insulin glargine, the Treat-to-Target Trial, was randomized, open-label and 24 weeks long, in 756 overweight adults with type 2 diabetes ⁸. Their HbA1c was above 7.5 percent on one or two oral medicines, and they added glargine or NPH at bedtime ⁸. HbA1c at the end was 6.96 percent on glargine and 6.97 on NPH, and about 60 percent on each reached 7 percent or lower ⁸.

The share reaching it without a documented nighttime low was 33.2 percent on glargine and 26.7 percent on NPH, P below 0.05 ⁸. P is the probability that chance alone would produce a gap that large. Of the 756, 367 took glargine and 389 NPH, and weight rose 3.0 kilograms on glargine and 2.8 on NPH ⁸.

The largest trial on the Lantus label is ORIGIN, an open-label, randomized trial in 12,537 adults aged 50 or older ³. They had abnormal glucose levels or early type 2 diabetes, and heart or vessel disease or risk factors for it ³. It tested whether Lantus would lower major cardiovascular events against standard care, over a median 6.2 years ³. The label reports that the incidence of major cardiovascular outcomes "was similar between groups" ³.

The first main endpoint, cardiovascular death, nonfatal heart attack or nonfatal stroke, occurred in 1,041 of 6,264 on Lantus and 1,013 of 6,273 on standard care ³. The hazard ratio was 1.02, with a 95 percent confidence interval of 0.94 to 1.11; a ratio of 1 means no difference ³. Cancer of any type had a hazard ratio of 0.99, with a 95 percent confidence interval of 0.88 to 1.11 ³.

Insulin detemir's label rests on open-label, randomized trials against NPH insulin in 1,155 adults and 347 children with type 1 diabetes and 869 adults with type 2 ¹. Its summary: "In general, the reduction in HbA1c with LEVEMIR® was similar to that with NPH insulin or insulin glargine" ¹. In a 24-week trial, 476 adults with type 2 diabetes who had never used insulin added Levemir or NPH to their pills ¹. HbA1c fell 2.0 percentage points in the 237 on Levemir and 2.1 in the 239 on NPH ¹. The difference was 0.1 points, with a 95 percent confidence interval of minus 0.0 to 0.3 ¹.

One Levemir trial enrolled 988 adults with type 2 diabetes on metformin, a diabetes pill, some of them on a second pill as well ¹. All first took liraglutide for 12 weeks ¹. Elsewhere the label points to this study where it speaks of use with "a GLP-1 receptor agonist," a medicine that acts like the gut hormone GLP-1 ¹.

The 323 whose HbA1c stayed at 7 percent or above were then randomized: 162 added Levemir and 161 continued unchanged ¹. Adding Levemir "resulted in statistically significant reductions in HbA1c" against continuing unchanged, the label says ¹. HbA1c fell 0.5 points with Levemir added and did not change without it, a difference of 0.5 (95 percent interval 0.4 to 0.7) ¹.

None of the sources cited here studies these three insulin analogs for weight loss, wellness or performance ¹, ⁸, ², ³. On the Humalog and Lantus labels, healthy volunteers appear only in studies of how each insulin is absorbed and acts ², ³. Standard two-year animal studies of cancer risk "have not been performed" for insulin lispro or insulin detemir ¹, ². Levemir's label cautions against setting one trial's rates beside another's, saying such comparisons "may be misleading" ¹.

What are the side effects?

Lantus's label calls hypoglycemia, low blood sugar, "the most common adverse reaction associated with insulins," and the Humalog and Levemir labels say the same of theirs ¹, ², ³. The Lantus and Levemir labels warn: "Severe hypoglycemia can cause seizures, may be life-threatening or cause death" ¹, ³. All three add that it "can impair concentration ability and reaction time," and they name driving and using machinery as times of risk ¹, ², ³.

How often it was severe varied by trial. In Humalog's 12-month type 1 trial, severe hypoglycemia meant an episode the patient could not treat alone ². It occurred in 14 of 81 (17 percent) on Humalog and 18 of 86 (21 percent) on regular insulin ². In its type 2 crossover study the figure was 2 percent on each ².

In Lantus's three adult type 1 trials, severe symptomatic hypoglycemia ranged from 6.5 to 10.6 percent on Lantus and 5.2 to 15.0 percent on NPH ³. In its three type 2 trials it ranged from 0.4 to 7.8 percent on Lantus and 1.1 to 11.9 percent on NPH ³. In ORIGIN's hypoglycemia table, it was 5.6 percent of 6,231 on Lantus and 1.8 percent of 6,273 on standard care ³.

On Levemir, severe hypoglycemia occurred in 5.0 to 8.7 percent of adults with type 1 diabetes across three trials ¹. Across three type 2 trials it ranged from none of 163 to 1.5 percent of 195 on Levemir ¹. The label prints these rates for the Levemir arms and says comparing them with other products' rates "may be misleading" ¹.

All three labels list weight gain ¹, ², ³. Humalog's label says, "Weight gain can occur with insulins, including HUMALOG, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria" ². Anabolic means building up the body's stores, and glucosuria is sugar lost in the urine, which falls as blood sugar comes under control. The Lantus and Levemir labels say the same of their drugs, in nearly the same words ¹, ³.

The trials put numbers on it, by arm. In Humalog's type 1 trial, mean weight rose 1.4 kilograms on Humalog and 1.0 on regular insulin over 12 months ². In its type 2 study, mean weight rose 0.8 kilograms on Humalog and 0.9 on regular insulin, each over three months ².

In Lantus's 52-week type 2 trial, weight rose 2.0 kilograms on Lantus and 1.9 on NPH ³. In a five-year type 2 trial reported on the same label, weight rose 3.7 kilograms in the 513 on Lantus and 4.8 in the 504 on NPH ³. In ORIGIN, the mean weight change was "2.2 kg greater in the LANTUS group than in the standard care group" ³.

On Levemir, the mean weight change across the label's trials ranged from minus 0.3 to plus 0.5 kilograms in adults with type 1 diabetes ¹. In adults with type 2 diabetes it ranged from plus 0.5 to plus 1.2 kilograms on Levemir ¹. The label gives these ranges for the Levemir arms of Studies A, B and C and of Studies E, F and H ¹. In the liraglutide trial, both randomized groups stayed on liraglutide and metformin ¹. From a mean of 96 kilograms, weight fell 0.3 kilograms in those who added Levemir and 1.1 in those who did not ¹.

All three labels warn of hypokalemia, low blood potassium ¹, ², ³. Humalog's says insulins "cause a shift in potassium from the extracellular to intracellular space," and that untreated hypokalemia "may cause respiratory paralysis, ventricular arrhythmia, and death" ².

All three warn of allergy too ¹, ², ³. Humalog's label says, "Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including HUMALOG" ². Anaphylaxis is an allergic reaction of the whole body that can kill.

Each also warns about a class of diabetes pills, the thiazolidinediones ¹, ², ³. The Lantus and Levemir labels say these "can cause dose-related fluid retention, when used in combination with insulin," and that it "may lead to or exacerbate heart failure" ¹, ³. The same two labels warn against sharing pens, needles or syringes between patients, because sharing "poses a risk for transmission of blood-borne pathogens" ¹, ³. Levemir's label says, "Accidental mix-ups between insulin products have been reported," and puts any change of insulin regimen "under close medical supervision" ¹.

At the injection site, Humalog's label says long-term use "can cause lipodystrophy," a thickening or thinning of the fat under the skin ². Reports since approval for Lantus and Levemir add localized cutaneous amyloidosis, a protein deposit in the skin at the site ¹, ³. Injection site pain was reported in 2.7 percent on Lantus against 0.7 percent on NPH in adult studies ³. The labels also list swelling from sodium retention, rash and itching ¹, ², ³. Humalog's label covers pump use, where a malfunction "can rapidly lead to hyperglycemia and ketoacidosis" ²; the Lantus and Levemir labels say not to use a pump ¹, ³.

Upper respiratory tract infection was reported in 22.4 percent of 1,257 adults with type 1 diabetes on Lantus and 23.1 percent of 1,070 on NPH ³. In Humalog's type 1 trial, headache was reported in 29.6 percent of 81 on Humalog and 22.1 percent of 86 on regular insulin ².

None of the three labels carries a boxed warning, FDA's strongest ¹, ², ³. Each contraindicates its drug during episodes of hypoglycemia, and in patients with hypersensitivity to the insulin or its inactive ingredients ¹, ², ³.

On pregnancy, Humalog's label says published studies "have not reported an association" with major birth defects, miscarriage or adverse outcomes ². Lantus's says they "have not reported a clear association" with adverse developmental outcomes, and Levemir's says the data "have not identified a drug-associated risk" ¹, ³. Each adds: "There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy" ¹, ², ³.

In sport

Insulins are named on WADA's 2026 Prohibited List ⁹. The list is the World Anti-Doping Agency's international standard of substances and methods barred to athletes under its code. Its section S4 opens, "The following hormone and metabolic modulators are prohibited" ⁹. Class S4.4.2, under metabolic modulators, reads "Insulins and insulin-mimetics, e.g. S519, S597" ⁹.

Insulin-mimetics are substances that act as insulin does, and S519 and S597 are the list's two examples. The section is headed "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" ⁹. The list names insulins as a class, and it does not name insulin lispro, insulin glargine or insulin detemir one by one ⁹.

What JumpstartMD offers

JumpstartMD does not prescribe insulin analogs. Our peptide library covers them so you have the facts on their FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.